Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH

Group to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut allergy candidate vaccine VLP platform to be combined with Allergy Therapeutics’ proprietary adjuvant technology Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy …